Abstract 170P
Background
The synergic combination of anti-PD-1/PD-L1 and antiangiogenic agents has exhibited as an encourage treatment pattern in aHCC. Multi-targeted antiangiogenic TKIs, such as lenvatinib and sorafenib, are approved for 1st-line treatment of aHCC. Sintilimab, a novel selective anti-PD-1 monoclonal antibody, has demonstrated encouraging clinical activities in aHCC. The trial aims to explore the safety and efficacy of sintilimab plus anlotinib (a TKI against angiogenesis) in aHCC.
Methods
This is a single-arm phase II study. Pts with aHCC, BCLC stage C or B (not amenable for surgery and chemoembolization), Child-Pugh scores≤7 and ECOG PS ≤ 1 received 1st-line treatment of sintilimab (200mg, iv, D1) plus anlotinib (12mg, po, QD, D1-14) every 3 wks until disease progression or unacceptable toxicity. Primary endpoints were safety and objective response rate (ORR, per RECIST 1.1), and secondary endpoints included disease control rate (DCR), progression free survival (PFS), duration of response (DOR) and overall survival (OS).
Results
As of June 30, 2020, 16 pts with 14 males, median age 56 yrs (range 41-70), BCLC B /C (3/13), and Child-Pugh A/B7(15/1) were enrolled. All pts received at least two cycles of treatments with median cycles 7 (range 2-18). Median follow-up was 5.3 months (range 2.1-13.3). The most common treatment-related adverse events (TRAEs) were grade 1-2 with thrombocytopenia (50%), increased AST (37.5%), ALT (31.3%) and bilirubin (31.3%), decreased neutrophil count (31.3%), leukopenia (25%), hypertension (25%) and hand-foot syndrome (25%). 6 pts experienced manageable grade 3 TRAEs, and no grade 4/5. 7 pts required dose reduction of anlotinib (4 pts to 10 mg and 3 to 8 mg). No treatment withdraw caused by TRAEs. Of 14 evaluable pts, ORR was 42.9% (6/14) with 1 CR and 5 PR. 7 pts were SD, and DCR was 92.9% (13/14). Median DoR was not reached (95%CI: 9.0 months-not reached), and all the responses were ongoing at the data cutoff. 6m-PFS rate was 78.8% (95%CI: 38.1%-94.3%) and mPFS was unreached.
Conclusions
The combination of sintilimab and anlotinib showed promising clinical activities with manageable toxicity for first line treatment of aHCC. Enrolment is on-going to further validate the combination regimen.
Clinical trial identification
NCT04052152.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University.
Funding
Jiangsu province 333 high level Talents Project; Innovation Funds from Chinese Society of Clinical Oncology Youth Committee. Y-young2019-060; the Advanced Health Talent of Six-One Project of Jiangsu Province. LGY2017069; Joint Research Project by Southeast University and Nanjing Medical University. 3207027381; National Natural Science Foundation of China, 81472306; Key research and development program of Jiangsu Province.BE2016789.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session